• Abell TL, Kim CH, and Malagelada JR. Idiopathic cyclic nausea and vomiting – a disorder of gastrointestinal motility. Mayo Clin Proc. 1988;63(12):1169-75.
• Abrams DI, Couey P, Shade SB, Kelly ME, and Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011 Dec;90(6):844-51.
• American Academy of Pain Medicine (AAPM) Position Statement on National Decline in Opiod Prescribing. 23 April 2018.  Accessed 28 July 2018.
• Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, and Sacks HS. Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. J Pain. 2015 Dec;16(12):1221-1232.
• Balabonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, and Walsh SL. Oral cannabidiol does not produce a safety signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017 Mar 1;172:9-13.
• Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, and Zajicek J. The cannabinoids use in progressive inflammatory brain disease (CUPID) trial: a randomized double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015;19(12):vii-viii, xxv-xxxi, 1-187.
• Bradford AC, Bradford WD, Abraham A, and Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med. 2018 May 1;178(5):667-672.
• DEA, 2018. Accessed 27 July 2018.
• Epidiolex Label, updated 2018. Accessed 22 July 2018.
• Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, and Wright S. An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed
• Sativex (THC:CBD, nabiximols) oromucosal spray. Ther Clin Risk Manag. 2016 Nov 11;12:1667-1675.
• GW Pharma, 2018. Accessed 20 July 2018.
• Hanus LO, Meyer SM, Munoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016 Nov 23;33(12):1357-1392.
• Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA. 2015 Jun 23-30;313(24):2474-83. Erratum in: JAMA. 2016 Sep 6;316(9):995.
• Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and pain: A clinical review. Cannabis Cannabinoid Res. 2017;2(1):96-104.
• Hunault CC, Bocker KB, Stellato RK, Kenemans JL, de Vries I, and Meulenbelt J. Acute subjective effects after smoking joints containing up to 69 mg delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl). 2014 Dec;231(24):4723-33.
• Iowa House File 524. Accessed 28 June 2018.
• Iowa Department of Public Health, 2018. Accessed 27 August 2018.
• Karschner EL, Darwin WD, Goodwin RS, Wright S, and Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta-9 tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66-75.
• King LA. Legal controls on cannabimimetics: an international dilemma? Drug Test Anal. 2014 Jan-Feb;6(1-2):80-7.
• Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, and Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011 May 1;115(1-2):120-30.
• Mackie K and Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006 Apr 28;8(2):E298-306.
• Marinol Label, updated 2017. Accessed 27 July 2018.
• Mark Wallace, 2018. Phone interview conducted with Mark Wallace, MD on 31 July 2018.
• Mark Ware, 2018. Phone interview with Mark Ware, MD, conducted on 19 July 2018.
• Melville, Nancy. 2018. Medical Cannabis for Pain May Reduce Need for Opioids. Accessed 20 August 2018.
• Minnesota Department of Health, Office of Medical Cannabis. Intractable Pain Patients in the Minnesota Medical Cannabis Program: Experience of Enrollees During the First Five Months. St. Paul, MN 55164-0882
• Morales P, Hurst DP, and Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. Prog Chem Org Nat Prod. 2017;103:103-131.
• Minnesota Statute 152.125. Accessed 28 July 2018.
• Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Candaian Pain Society. Pain Res Manag. 2014;19(6):328-35.
• Nabilone Label, updated 2006. Accessed 21 July 2018.
• National Academies Press. The health effect of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies of Sciences, Engineering, and
• Medicine; Health and Medicine Division; Board on Population Health and Public Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The National Academies Collection: Reports Funded by the National Institutes of Health. 2017.
• NIDA, 2017. 
• NIDA, 2018a. 
• NIDA, 2018b. 
• Ridenhour TA, Lanza ST, Donny EC, and Clark DB. Different lengths of times for progressions in adolescent substance involvement. Addict Behav. 2006;31(6):962-983.
• Sativex Mongraph, updated 2015. Accessed 28 July 2018.
• Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, and Ware M. Cannabis in pain treatment: Clinical and research considerations. J Pain. 2016 Jun;17(6):654-68.
• Syndros Label, updated 2016. Accessed 23 July 2018.
• Wallace MS, Marcotte TD, Umlauf A, Gouaux B, and Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015 Jul;16(7):616-27.
• Ware MA, Wang T, Shapiro S, Collet JP, and COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015 Dec;16(12):1233-1242.
• Wen H and Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med. 2018;178(5):673-679.
• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, and Kelijnen J. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73.
• Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136-48.
• Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, and Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016 Sep;17(9):982-1000.
• WHO, 2018. Fortieth meeting of the Expert Committee on Drug Dependence. Pre-reviews on cannabis plant and resin, extracts and tinctures of cannabis, delta-9-tetrahydrocannabinol (THC), and isomers of THC.
• WHO CBD Report, 2018. Fortieth meeting of the Expert Committee on Drug Dependence. Critical Review: Cannabidiol.
• WHOCBDReportMay2018-2.pdf. Accessed 15 July 2018.
• Zou S and Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci. 2018 Mar 13;19(3).